VASTox Acquires Key Assets from MNL Pharma
VASTox's drug discovery pipeline and chemistry service capabilities strengthened by acquisition of MNL Pharma's key assets.
Released 14th December 2006

2006 Spinal Muscular Atrophy Programme Receives Grant from Leading Neuromuscular Charity
Released 1st November 2006

VASTox Announces Promising Results in Spinal Muscular Atrophy Drug Discovery Programme
VASTox has presented promising results from the spinal muscular atrophy (SMA) discovery programme at a leading neuroscience conference.
Released 17th October 2006

VASTox Host Analyst Day
VASTox host analyst day at Milton Park site in Oxfordshire.
Released 6th October 2006

Interim Results for the Six Months Ended 31 July 2006
Released 26th September 2006

VASTox Awarded £910,000 Grant from DTI for Stem Cell Research
VASTox will provide a new proprietary drug discovery programme in the stem cell area supported by grant funding from the UK Department of Trade and Industry.
Released 20th September 2006

VASTox Provide Grant to Support DMD Patient Registry
VASTox has provided a grant to Parent Project UK (PPUK) to support the development and management of its Duchenne Muscular Dystrophy patient registry.
Released 1st August 2006

VASTox Strengthens Global Patent Position in Duchenne Muscular Dystrophy
A wide ranging patent has been granted by the Australian Patent Office relating to VASTox's novel approach towards the treatment of DMD.
Released 13th July 2006

Appointment of Chief Commercial Officer
VASTox announces the appointment of James Taylor to the Board of Directors as the company's new Chief Commercial Officer.
Released 12th July 2006

VASTox receives positive opinion from EMEA for its DMD therapy
EMEA has recommended awarding orphan drug designation to VASTox's therapy for Duchenne Muscular Dystrophy (DMD).
Released 22nd June 2006

VASTox Becomes a Partner in Neuromuscular Disease Network
VASTox has become a partner in TREAT-NMD, a network of excellence focussed on the treatment of neuromuscular diseases. TREAT–NMD has been awarded a €10M European Union grant for collaborative research.
Released 31st May 2006

VASTox Appoint Professor George Fleet as Carbohydrate Chemistry Consultant
VASTox strengthens its carbohydrate chemistry team through the appointment of the world expert on carbohydrate chemistry, Professor George Fleet, University of Oxford
Released 18th May 2006

Preliminary Results for the Year Ended 31 January 2006
Released 9th May 2006

Appointment of Chief Financial Officer
VASTox plc announces that Darren Millington ACMA has joined the Board of Directors as Chief Financial Officer
Released 9th May 2006

Appointment of Chief Scientific Officer
VASTox plc announces the appointment of Dr Richard Storer as Chief Scientific Officer
Released 26th April 2006

Commencement of a fifth proprietary drug discovery programme
VASTox Plc announces the commencement of a fifth proprietary drug discovery programme which is focused on the Wnt signalling pathway for cancer.
Released 11th April 2006

VASTox plc raise £10.45 million through the issue of new ordinary shares
VASTox Plc has raised £10.45 million through the issue of new ordinary shares to institutional investors and also reports pre-close update.
Released 27th February 2006

Positive Preclinical Results in the Duchenne Muscular Dystrophy Programme
VASTox announces positive preclinical results in its lead Duchenne muscular dystrophy programme.
Released 24th January 2006